HUE038342T2 - Kétfunkciós polipeptidek - Google Patents
Kétfunkciós polipeptidekInfo
- Publication number
- HUE038342T2 HUE038342T2 HUE16176249A HUE16176249A HUE038342T2 HU E038342 T2 HUE038342 T2 HU E038342T2 HU E16176249 A HUE16176249 A HU E16176249A HU E16176249 A HUE16176249 A HU E16176249A HU E038342 T2 HUE038342 T2 HU E038342T2
- Authority
- HU
- Hungary
- Prior art keywords
- bifunctional polypeptides
- bifunctional
- polypeptides
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0908613.3A GB0908613D0 (en) | 2009-05-20 | 2009-05-20 | T Cell Reseptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE038342T2 true HUE038342T2 (hu) | 2018-10-29 |
Family
ID=40834242
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10720803A HUE032929T2 (hu) | 2009-05-20 | 2010-05-19 | Bifunkcionális polipeptidek |
| HUE16176246A HUE043245T2 (hu) | 2009-05-20 | 2010-05-19 | Bifunkcionális polipeptidek |
| HUE16176249A HUE038342T2 (hu) | 2009-05-20 | 2010-05-19 | Kétfunkciós polipeptidek |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10720803A HUE032929T2 (hu) | 2009-05-20 | 2010-05-19 | Bifunkcionális polipeptidek |
| HUE16176246A HUE043245T2 (hu) | 2009-05-20 | 2010-05-19 | Bifunkcionális polipeptidek |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US10130721B2 (hu) |
| EP (3) | EP3112377B1 (hu) |
| JP (4) | JP5667171B2 (hu) |
| CN (1) | CN102439034B (hu) |
| AU (1) | AU2010250951B2 (hu) |
| BR (1) | BRPI1013029A2 (hu) |
| CA (2) | CA2762604C (hu) |
| CY (3) | CY1118405T1 (hu) |
| DK (3) | DK3112377T3 (hu) |
| EA (1) | EA020841B1 (hu) |
| ES (3) | ES2608653T3 (hu) |
| GB (1) | GB0908613D0 (hu) |
| HR (3) | HRP20170086T1 (hu) |
| HU (3) | HUE032929T2 (hu) |
| LT (3) | LT2432802T (hu) |
| MX (1) | MX340168B (hu) |
| PL (3) | PL3112377T3 (hu) |
| PT (3) | PT2432802T (hu) |
| SI (3) | SI2432802T1 (hu) |
| TR (2) | TR201905437T4 (hu) |
| WO (1) | WO2010133828A1 (hu) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| LT2665486T (lt) | 2011-01-18 | 2020-04-10 | Bioniz, Llc | Kompozicijos, skirtos gama-c-citokino aktyvumui moduliuoti |
| PT2755997T (pt) * | 2011-09-15 | 2018-10-30 | Us Health | Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7 |
| WO2013048243A1 (en) * | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| US8524234B2 (en) | 2011-11-03 | 2013-09-03 | Tolera Therapeutics, Inc | Antibody for selective inhibition of T-cell responses |
| EP2802356A1 (en) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| CN106164091A (zh) | 2014-03-14 | 2016-11-23 | 英美偌科有限公司 | Tcr文库 |
| CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| JP6415716B2 (ja) | 2014-11-07 | 2018-10-31 | グアンドン シャンスエ ライフ サイエンス， リミテッド． | 可溶性のヘテロ二量体ｔ細胞受容体およびその製法と使用 |
| GB201516269D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516265D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516270D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516275D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| GB201516277D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR libraries |
| GB201516274D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| US11400134B2 (en) | 2015-10-09 | 2022-08-02 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520548D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607535D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520562D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520543D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520597D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2018083505A1 (en) | 2016-11-07 | 2018-05-11 | Immunocore Limited | Peptides |
| GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520575D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
| GB201520567D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520536D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520542D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520546D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520545D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520603D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520557D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520570D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| LT3430037T (lt) * | 2016-03-16 | 2022-12-12 | Immatics Biotechnologies Gmbh | Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją |
| GB201604953D0 (en) | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| ES2914648T3 (es) | 2016-04-08 | 2022-06-15 | Immunocore Ltd | Receptores de células T |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| MX2018014863A (es) | 2016-06-02 | 2019-09-11 | Immunocore Ltd | Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3. |
| WO2018081784A1 (en) * | 2016-10-31 | 2018-05-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells for expanding immune cells for immunotherapy |
| CN108203459A (zh) * | 2016-12-19 | 2018-06-26 | 广东香雪精准医疗技术有限公司 | 源自于prame的肿瘤抗原短肽 |
| GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| CA3100253A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| KR20210116478A (ko) * | 2019-01-14 | 2021-09-27 | 난징 레전드 바이오테크 씨오., 엘티디. | 키메라 수용체 폴리펩티드 및 이의 용도 |
| WO2020148372A1 (en) | 2019-01-17 | 2020-07-23 | Immunocore Limited | Formulations |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| CN113396230A (zh) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | 癌症的诊断和治疗方法 |
| GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| CN113906140A (zh) | 2019-03-18 | 2022-01-07 | 路德维格癌症研究院 | A2/ny-eso-1特异性t细胞受体及其用途 |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20240327491A1 (en) | 2021-07-12 | 2024-10-03 | Ludwig Institute For Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
| AU2023222190A1 (en) | 2022-02-20 | 2024-08-29 | Immunocore Limited | Hiv-specific binding molecules and tcr |
| WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| TW202417476A (zh) | 2022-08-18 | 2024-05-01 | 英商英美偌科有限公司 | Ｔ細胞受體及其融合蛋白 |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024067821A1 (zh) * | 2022-09-30 | 2024-04-04 | 瑅安生物医药（杭州）有限公司 | 一种修饰细胞及其用途 |
| WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024146936A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
| WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| CA2328144A1 (en) * | 1998-05-19 | 1999-11-25 | Avidex Limited | Multivalent t cell receptor complexes |
| ES2293748T3 (es) * | 1998-10-21 | 2008-03-16 | Altor Bioscience Corporation | Moleculas de fijacion poliespecificas y usos de las mismas. |
| US20040253632A1 (en) * | 2000-05-25 | 2004-12-16 | Sunol Molecular Corporation | Modulation of T -cell receptor interactions |
| CN101712721A (zh) * | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
| CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| JP4436319B2 (ja) | 2002-10-09 | 2010-03-24 | メディジーン リミテッド | 単鎖組換えｔ細胞レセプター |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| NZ550810A (en) | 2004-05-19 | 2009-05-31 | Immunocore Ltd | High affinity NY-ESO T cell receptor |
| US20090042285A1 (en) | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
| EP1773383B1 (en) | 2004-05-27 | 2012-09-12 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| EP1763365B1 (en) | 2004-06-09 | 2016-08-10 | Technion Research And Development Foundation, Ltd. | Antibodies for selective apoptosis of cells |
| CA2582963A1 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| EP2527370A1 (en) * | 2005-12-21 | 2012-11-28 | Amgen Research (Munich) GmbH | Compounds having resistance to soluble CEA |
| RU2008129827A (ru) * | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| GB0816096D0 (en) | 2008-09-04 | 2008-10-15 | Medigene Ltd | Diabetes t cell receptors |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
-
2009
- 2009-05-20 GB GBGB0908613.3A patent/GB0908613D0/en not_active Ceased
-
2010
- 2010-05-19 MX MX2011012184A patent/MX340168B/es active IP Right Grant
- 2010-05-19 EP EP16176249.7A patent/EP3112377B1/en not_active Revoked
- 2010-05-19 HU HUE10720803A patent/HUE032929T2/hu unknown
- 2010-05-19 CA CA2762604A patent/CA2762604C/en active Active
- 2010-05-19 SI SI201031358A patent/SI2432802T1/sl unknown
- 2010-05-19 US US13/319,597 patent/US10130721B2/en active Active
- 2010-05-19 WO PCT/GB2010/000988 patent/WO2010133828A1/en active Application Filing
- 2010-05-19 DK DK16176249.7T patent/DK3112377T3/en active
- 2010-05-19 PT PT107208035T patent/PT2432802T/pt unknown
- 2010-05-19 JP JP2012511333A patent/JP5667171B2/ja active Active
- 2010-05-19 PL PL16176249T patent/PL3112377T3/pl unknown
- 2010-05-19 CA CA2968393A patent/CA2968393C/en active Active
- 2010-05-19 LT LTEP10720803.5T patent/LT2432802T/lt unknown
- 2010-05-19 LT LTEP16176246.3T patent/LT3112376T/lt unknown
- 2010-05-19 DK DK16176246.3T patent/DK3112376T3/en active
- 2010-05-19 LT LTEP16176249.7T patent/LT3112377T/lt unknown
- 2010-05-19 CN CN201080022523.6A patent/CN102439034B/zh active Active
- 2010-05-19 ES ES10720803.5T patent/ES2608653T3/es active Active
- 2010-05-19 SI SI201031697T patent/SI3112377T1/en unknown
- 2010-05-19 PT PT161762497T patent/PT3112377T/pt unknown
- 2010-05-19 EP EP16176246.3A patent/EP3112376B1/en not_active Revoked
- 2010-05-19 PT PT16176246T patent/PT3112376T/pt unknown
- 2010-05-19 HU HUE16176246A patent/HUE043245T2/hu unknown
- 2010-05-19 DK DK10720803.5T patent/DK2432802T3/en active
- 2010-05-19 ES ES16176246T patent/ES2721058T3/es active Active
- 2010-05-19 PL PL10720803T patent/PL2432802T3/pl unknown
- 2010-05-19 TR TR2019/05437T patent/TR201905437T4/tr unknown
- 2010-05-19 BR BRPI1013029A patent/BRPI1013029A2/pt not_active Application Discontinuation
- 2010-05-19 EP EP10720803.5A patent/EP2432802B1/en active Active
- 2010-05-19 TR TR2018/09945T patent/TR201809945T4/tr unknown
- 2010-05-19 EA EA201101660A patent/EA020841B1/ru not_active IP Right Cessation
- 2010-05-19 ES ES16176249.7T patent/ES2672095T3/es active Active
- 2010-05-19 PL PL16176246T patent/PL3112376T3/pl unknown
- 2010-05-19 HU HUE16176249A patent/HUE038342T2/hu unknown
- 2010-05-19 SI SI201031883T patent/SI3112376T1/sl unknown
- 2010-05-19 AU AU2010250951A patent/AU2010250951B2/en active Active
-
2014
- 2014-12-11 JP JP2014250885A patent/JP2015096527A/ja active Pending
-
2016
- 2016-12-30 CY CY20161101365T patent/CY1118405T1/el unknown
-
2017
- 2017-01-19 HR HRP20170086TT patent/HRP20170086T1/hr unknown
- 2017-01-23 JP JP2017009529A patent/JP2017110019A/ja active Pending
-
2018
- 2018-05-04 CY CY20181100507T patent/CY1120439T1/el unknown
- 2018-05-15 HR HRP20180757TT patent/HRP20180757T1/hr unknown
- 2018-10-03 US US16/151,144 patent/US20190247512A1/en not_active Abandoned
-
2019
- 2019-04-08 US US16/378,505 patent/US10420846B2/en active Active
- 2019-04-08 US US16/378,481 patent/US10517960B2/en active Active
- 2019-04-08 US US16/378,501 patent/US10576162B2/en active Active
- 2019-04-09 HR HRP20190674TT patent/HRP20190674T1/hr unknown
- 2019-04-12 CY CY20191100410T patent/CY1121558T1/el unknown
- 2019-05-08 JP JP2019088405A patent/JP2019172678A/ja active Pending
-
2022
- 2022-09-02 US US17/929,682 patent/US20230241238A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180757T1 (hr) | Bifunkcionalni polipeptidi | |
| HRP20191852T8 (hr) | Polipeptidi | |
| HK1209761A1 (en) | Polypeptides | |
| GB201015582D0 (en) | Improved materials | |
| GB201116695D0 (en) | Container assembly | |
| ZA201200594B (en) | Materials | |
| GB0914823D0 (en) | The feedifier | |
| GB0920283D0 (en) | The doggybreathe | |
| GB0809659D0 (en) | Polypeptides | |
| GB201019124D0 (en) | The cupster | |
| GB0910466D0 (en) | Fusion polypeptides | |
| GB0910319D0 (en) | Fusion polypeptides | |
| GB0904217D0 (en) | Binding polypeptides | |
| GB201002546D0 (en) | The ipouch | |
| GB0907845D0 (en) | The hoppon | |
| GB0916219D0 (en) | The ingestor | |
| GB0912501D0 (en) | The k-rimp | |
| GB0911596D0 (en) | The all-weatherer | |
| GB0910238D0 (en) | The leany | |
| GB0906476D0 (en) | The logarhythm | |
| GB0904988D0 (en) | The feed-eezy |